

WHAT IS CLAIMED IS:

1. An immediate-release oral pharmaceutical formulation comprising a therapeutically effective amount of ezogabine and one or more pharmaceutically acceptable excipients.
2. The immediate-release oral pharmaceutical formulation of Claim 1 comprising two or more pharmaceutically acceptable excipients.
3. The immediate-release oral pharmaceutical formulation of any one of Claims 1-2, wherein each pharmaceutically acceptable excipient is present in a concentration of from about 0.01% w/w to about 99% w/w.
4. The immediate-release oral pharmaceutical formulation of any one of Claims 1-3, wherein ezogabine is present in a concentration of from about 1% w/w to about 30% w/w.
5. The immediate-release oral pharmaceutical formulation of any one of Claims 1-4 comprising ezogabine at a concentration of about 20% w/w; HPMC at a concentration of about 5.0% w/w; starch at a concentration of about 20% w/w; MCC at a concentration of about 45% w/w; butylated hydroxytoluene at a concentration of about 0.01% w/w; and crospovidone at a concentration of about 10.0% w/w of the immediate-release oral pharmaceutical formulation.
6. A method of treating epilepsy and/or an epileptic seizure disorder in a mammal, wherein the method comprises orally administering to the mammal in need thereof an immediate-release oral pharmaceutical formulation comprising a therapeutically effective amount of ezogabine and one or more pharmaceutically acceptable excipients.
7. The method of Claim 6, wherein the mammal is a human.
8. The method of any one of Claims 6-7 wherein the human is a child.
9. The method of any one of Claims 6-8 wherein the epilepsy and/or an epileptic seizure disorder is KCNQ2-related neonatal developmental and epileptic encephalopathy.

10. The method of any one of Claims 6-9 wherein the immediate-release oral pharmaceutical formulation comprises two or more pharmaceutically acceptable excipients.

11. The method of any one of Claims 6-10 wherein each pharmaceutically acceptable excipient is present in a concentration of from about 0.01% w/w to about 99% w/w.

12. The method of any one of Claims 6-11 wherein ezogabine is present in a concentration of from about 1% w/w to about 30% w/w.

13. The method of any one of Claim 6-12 wherein the immediate release oral pharmaceutical formulation comprises ezogabine at a concentration of about 20% w/w; HPMC at a concentration of about 5.0% w/w; starch at a concentration of about 20% w/w; MCC at a concentration of about 45% w/w; butylated hydroxytoluene at a concentration of about 0.01% w/w; and crospovidone at a concentration of about 10.0% w/w of the immediate-release oral pharmaceutical formulation.

14. A method of preparing an immediate-release oral pharmaceutical formulation comprising comprising a therapeutically effective amount of ezogabine and one or more pharmaceutically acceptable excipients.

15. The method of Claim 14 wherein the immediate-release oral pharmaceutical formulation comprises a therapeutically effective amount of ezogabine and two or more pharmaceutically acceptable excipients.

16. The method of any one of Claims 14-15, wherein each pharmaceutically acceptable excipient is present in a concentration of from about 0.01% w/w to about 99% w/w.

17. The method of any one of Claims 14-16, wherein ezogabine is present in a concentration of from about 1% w/w to about 30% w/w.

18. The method of any one of Claims 14-17, wherein the immediate-release formulation comprises ezogabine at a concentration of about 20% w/w; HPMC at a concentration of about 5.0% w/w; starch at a concentration of about 20% w/w; MCC at a concentration of about 45% w/w; butylated hydroxytoluene at a concentration of about 0.01% w/w; and crospovidone at a concentration of about 10.0% w/w of the

immediate-release oral pharmaceutical formulation.